Research

Jacobson’s story of battling illness while teaching featured in UCSF Magazine

Wed Feb 17, 2021

Gabriela Hasbun

Matthew Jacobson, PhD

A UCSF Magazine feature traces a School faculty member’s journey as both a patient and teacher.

Cancer drug stops SARS-CoV-2 in the lab

Thu Feb 11, 2021

PharmaMar

Aplidin is extracted from Aplidium albicans, a sea squirt found off the coast of Spain.

“If you get a drug that targets a human protein, it would be incredibly hard for the virus to mutate away from being reliant on it,” said Nevan Krogan, the director of QBI.

Synthetic biomaterial guides cancer therapy to hidden tumors

Wed Jan 20, 2021

Tejal Desai, PhD, and colleagues took inspiration from the structure of DNA to engineer a biomaterial that promises to improve CAR-T cell therapy for various cancers.

Advance opens up new possibilities for CAR T-cell therapy to treat a variety of cancers

Autobahn collaboration to accelerate UCSF innovation from bench to bedside

Fri Jan 8, 2021

How we know it’s safe to get the vaccine

Thu Dec 17, 2020

A man wearing a mask measures vaccine in a syringe.

Susan Merrell

Preparing the Pfizer vaccine for injection.

UCSF experts address the safety of the new COVID-19 vaccines

A genetic shortcut to help visualize proteins at work

Fri Dec 11, 2020

Jamming the gears of a deadly virus

Fri Nov 13, 2020

NIH

A 3D printed model of a SARS-CoV-2 viral particle (blue) dotted with the spike protein (red) that enables the virus to infect human cells. The spike protein is the target of research efforts to prevent and treat COVID-19.

Team efforts at the School and beyond produce two potential treatments for COVID-19.

Publication Highlight: Meghan Whalen - Aweeka Lab

Thu Nov 12, 2020

Student Publication Highlight:

Resistant bacteria meet their match with custom antibiotics

Mon Oct 26, 2020

Paul Gunning (Cell Image Library)

A scanning electron micrograph image of methicillin resistant staphylococcus aureus (MRSA) bacteria.

“Molecular building blocks” give antibiotics an edge over drug-resistant bacteria.

QBI probes three lethal coronaviruses to find possible drug targets

Fri Oct 23, 2020

Blue dots show MERS-CoV particles on the surface of a cell

National Institute of Allergy and Infectious Diseases (NIAID)

Middle East respiratory syndrome coronavirus (MERS-CoV) viral particles under an electron microscopic.

“This is looking across coronaviruses and finding the commonalities so we’re in a better position to attack SARS3 when it comes,” said Nevan Krogan, the director of QBI.

Categories: Research